MaaT Pharma (MAAT) KOL Event summary

Introduction and agenda

• The event focused on MaaT013's development and clinical data for GVHD, featuring presentations from Prof. Mohamad Mohty, Dr. Monzr M. Al Malki, and Hervé Affagard, with a Q&A session.

• The agenda included company introduction, KOL presentations, early access program results, unmet need for MaaT013 in GVHD, and discussion of next steps.

KOL background and credentials

• Professor Mohty is a globally recognized expert in GVHD and HSCT, with over 1,000 peer-reviewed publications.

• Dr. Monzr Al-Malki is the director of blood and marrow transplant at City of Hope and the first to treat a patient with MaaT013 in the U.S.

Market insights and analysis

• Acute GVHD affects 20-50% of allogeneic HSCT patients, with about 12,000 cases annually in the US and Europe and high mortality, especially with GI involvement.

• There is a significant unmet need for effective third-line therapies, as current options have limited efficacy, no FDA approval, and 85% one-year mortality.

• MaaT013 is positioned as the most advanced product in 3L, with increasing demand, global early access, and estimated €250m market potential in 3L alone.

• Increasing clinical adoption and revenue growth for MaaT013, with €2.3m generated in France and in the first nine months of 2024.